Mario Caccese
Overview
Explore the profile of Mario Caccese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cerretti G, Bosio A, Librizzi G, Pintacuda G, Caccese M, Salvalaggio A, et al.
J Neurooncol
. 2025 Mar;
PMID: 40063186
Purpose: Bevacizumab is an anti-angiogenetic treatment that can be used in patients with recurrent glioblastoma, but there are limited and controversial data on the optimal dose and schedule, associated toxicities...
2.
Cella E, Bosio A, Persico P, Caccese M, Padovan M, Losurdo A, et al.
Cancer Treat Rev
. 2024 Dec;
132:102866.
PMID: 39709267
No abstract available.
3.
Cella E, Bosio A, Persico P, Caccese M, Padovan M, Losurdo A, et al.
Cancer Treat Rev
. 2024 Nov;
131:102850.
PMID: 39531943
Gliomas are the most common primary malignant brain tumours in adults. Despite decades of research into novel therapeutic approaches, the prognosis remains poor. PARP1-2 are critical for DNA repair, cell...
4.
Crimi F, Turatto F, DAlessandro C, Sussan G, Iacobone M, Torresan F, et al.
J Endocrinol Invest
. 2024 Oct;
48(3):711-720.
PMID: 39382628
Background: The adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy originating from the adrenal cortex. These patients usually undergo chemotherapy with etoposide, doxorubicin, cisplatin and mitotane (EDP-M) in...
5.
Ius T, Somma T, Pasqualetti F, Berardinelli J, Vitulli F, Caccese M, et al.
Oncol Lett
. 2024 Jul;
28(3):440.
PMID: 39081966
Despite the implementation of multimodal treatments after surgery, glioblastoma (GBM) remains an incurable disease, posing a significant challenge in neuro-oncology. In this clinical setting, local therapy (LT), a developing paradigm,...
6.
Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a fusion
Cerretti G, Padovan M, Guerriero A, Maccari M, Bosio A, Caccese M, et al.
Neurooncol Adv
. 2024 Jun;
6(1):vdae077.
PMID: 38845690
No abstract available.
7.
Pasqualetti F, Gabelloni M, Faggioni L, Aquaro G, De Vietro F, Mendola V, et al.
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592330
Clinical evidence suggests an association between comorbidities and outcome in patients with glioblastoma (GBM). We hypothesised that the internal carotid artery (ICA) calcium score could represent a promising prognostic biomarker...
8.
Di Nunno V, Lombardi G, Simonelli M, Minniti G, Mastronuzzi A, Di Ruscio V, et al.
J Neurooncol
. 2024 Mar;
167(1):145-154.
PMID: 38457090
Purpose: Adult Diffuse midline glioma (DMG) is a very rare disease. DMGs are currently treated with radiotherapy and chemotherapy even if only a few retrospective studies assessed the impact on...
9.
Pace A, Lombardi G, Villani V, Benincasa D, Abbruzzese C, Cestonaro I, et al.
Front Oncol
. 2024 Jan;
13:1320710.
PMID: 38162492
Introduction: Drug repurposing is a promising strategy to develop new treatments for glioblastoma. In this phase II clinical trial, we evaluated the addition of chlorpromazine to temozolomide in the adjuvant...
10.
Cerretti G, Pessina F, Franceschi E, Barresi V, Salvalaggio A, Padovan M, et al.
Front Oncol
. 2023 Dec;
13:1301179.
PMID: 38074692
Ependymomas are rare glial tumors with clinical and biological heterogeneity, categorized into supratentorial ependymoma, posterior fossa ependymoma, and spinal cord ependymoma, according to anatomical localization. Spinal ependymoma comprises four different...